spacer
home > ebr > spring 2018 > sudden impact
PUBLICATIONS
European Biopharmaceutical Review

Sudden Impact

The development of biological therapeutics such as humanised antibodies has led to remarkable clinical benefits in many indications. Despite this success, the induction of anti-drug antibodies (ADAs) due to the potential immunogenicity of these therapeutics remains a significant challenge to the successful development of biotherapeutics.

The decades that followed the approval of the first biotherapeutic (Insulin, 1982) have seen a dramatic increase in both the number and rate of approvals. Biologics now account for over 30% of licensed pharmaceutical products and over 25% of the new drugs approved by The Center for Drug Evaluation and Research in 2015. For monoclonal antibodies (mAbs) alone, since the commercialisation of the first mAb in 1986, this class of product has increased significantly. By 2014, 47 mAb products had been approved in the US and Europe. At the current approval rate, it can be anticipated that approximately 70 mAb products will be on the market by 2020, with combined worldwide sales of nearly US$125 billion (1).

Despite this success, biologics can elicit immunological responses when administered to patients, which can affect their safety and efficacy. These side effects fall into two categories: pharmacological (largely predictable adverse reactions resulting from the interaction between the biologic and its target) and non-pharmacological. Non-pharmacological adverse events contain immunotoxicity, which includes both immuneresponseand non-immune response-mediated reactions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Gary Bembridge is Senior Director of scientific affairs (immunology) at Abzena. Since joining the company in 2013, he has managed business development activities associated with immunological responses to biotherapeutics, ensuring that immunogenicity assessment and bespoke immunological studies are tailored to partners’ needs. Prior to this, Gary worked at Huntingdon Life Sciences (Envigo) as a Biopharmaceutical Product Development Manager and shared responsibility for designing safety studies and nonclinical development programmes for all biologics, providing scientific support and advice to the immunology department. He completed his PhD at the University of Bristol, UK, and the Department of Veterinary Medicine.

Dr Karen Hills is in marketing and business development at Abzena in Cambridge, UK. She is a consultant in pharma/biopharma business development and marketing. Since joining Abzena, Karen has focused on marketing across the areas of cell-line development, chemistry manufacturing, and immunology. Karen has a PhD in molecularb from Cambridge University, UK, and an MBA from the London Business School, UK. Her background includes sales, marketing, and business development for companies ranging from start-up biotech to Big Pharma.
spacer
Dr Gary Bembridge
spacer
spacer
spacer
Dr Karen Hills
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Dempsey Demystifies Regulatory Cycle at DIA Europe

March 22, 2018 (Hartford, Conn.) – RWS Life Sciences Managing Director, Sheena Dempsey, will present “Demystifying the Multilingual Complexities in the Regulatory Cycle” at DIA Europe 2018, on April 17, at 3:30PM (CET), in Basel, Switzerland.
More info >>

White Papers

Case Study: Emerade® Auto-Injector

SHL Group

The Emerade® Auto Injector is an intuitive disposable 2-step auto injector designed to deliver adrenaline via intramuscular injection during emergency use. The exterior of the device has a simple and sleek industrial design with the aim to minimize confusion for users. To achieve the penetration force required for an intramuscular injection while still ensuring the dosage is delivered correctly and needle protection mechanisms are in place, the Emerade Auto Injector is equipped with an advanced 3 spring technology. The device is also available in 3 doses (150mcg, 300mcg, 500mcg), with each recommended for patients of different bodyweights to maximize efficacy.
More info >>

 
Industry Events

BioTrinity 2018

23-25 April 2018, Novotel London West in Hammersmith

BioTrinity 2018 is taking place from 23-25 April at the Novotel London West in Hammersmith. Now in its 12th year, BioTrinity remains the leading life sciences biopartnering and investment conference in Europe, and is a must attend event for R&D companies, TTO’s and academia who are looking to meet, collaborate, partner and seek funding from Big Pharma, Investors and Associated Industry companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement